HB2202, titled the “End Taxpayer Funding of Gender Experimentation Act of 2025,” would bar the use of federal funds for gender transition procedures and prohibit federal health benefits coverage from including such procedures. It also would bar gender transition procedures from being performed in federal facilities or by federal employees acting within the scope of their employment. The bill defines “gender transition procedure” broadly to include a wide range of hormonal, surgical, and cosmetic interventions, while carving out exceptions for certain disorders of sex development, treatment of complications from prior procedures, emergency procedures needed to prevent death or major bodily impairment, and puberty-blocking drugs used for precocious puberty.
The bill would also amend tax and Affordable Care Act provisions to deny ACA premium tax credits, cost-sharing reductions, and certain small-employer health insurance credits for plans that cover gender transition procedures. At the same time, it expressly allows individuals, states, localities, employers, and non-federal insurers to purchase or offer separate coverage for these procedures if the coverage is paid entirely with non-federal funds and not with federal matching funds, including Medicaid matching funds. The bill would take effect generally one year after enactment for the ACA-related changes.
In practical terms, the bill would change federal funding rules across multiple parts of the U.S. Code and the Internal Revenue Code, and would affect federal health programs, federal facilities, federally subsidized insurance arrangements, and plans receiving ACA-related tax benefits. It would not directly ban private coverage of gender transition procedures, but it would make such coverage ineligible for specified federal subsidies and credits and would restrict federal participation in providing those services.
The available context shows no recorded committee debate or votes, so there is no documented floor or committee sentiment in the provided materials. Based on the bill text and title, the measure is clearly framed by its sponsor as a restriction on public funding for gender transition care, while its structure suggests an intent to preserve privately funded or separately financed coverage options. Because there are no transcripts or vote totals, the broader political reaction cannot be measured from the supplied record.
The main point of contention inherent in the bill is its treatment of gender-affirming care as a category of services that should be excluded from federal funding and federal health coverage. Supporters would likely view it as a taxpayer-funding prohibition and a limitation on federal involvement, while opponents would likely object to the breadth of the definition, the impact on transgender patients and health plans, and the ACA subsidy restrictions. The bill’s exceptions for disorders of sex development, emergency care, and precocious puberty may also be a point of legal and medical scrutiny because they narrow but do not eliminate the scope of the prohibition.
HB2202 would add a new federal statutory chapter in Title 1 of the U.S. Code prohibiting the expenditure of federal funds for gender transition procedures and for health benefits plans that cover them, and it would limit such procedures in federal facilities and by federal employees. It would also amend the Internal Revenue Code and ACA-related provisions to deny certain premium tax credits, cost-sharing reductions, and small-employer health insurance credits for plans covering gender transition procedures, while allowing separate non-federally funded coverage. The bill would affect federal agencies, federal health care providers, ACA marketplaces, insurers, employers, states, localities, and Medicaid-related financing arrangements.
No committee transcript or vote history was provided, so there is no documented legislative sentiment beyond the bill’s text and title. The measure is presented by its sponsor as a prohibition on taxpayer funding for gender transition procedures, indicating a strongly restrictive policy stance. The absence of recorded debate or votes means support and opposition cannot be quantified from the supplied materials.
The central controversy is whether federal funds and federal health programs should be allowed to support gender transition procedures at all. Likely supporters would emphasize taxpayer funding limits, federal facility restrictions, and the bill’s exceptions for certain medical conditions and emergency care. Likely opponents would focus on the breadth of the definition of gender transition procedures, the exclusion of ACA subsidies for plans that cover them, and the bill’s effect on transgender health care access. The carve-outs for disorders of sex development and complications from prior procedures may also draw scrutiny over how they would be applied in practice.